29 C
Vientiane
Thursday, June 19, 2025
spot_img
Home Blog Page 589

Seoul Opens Applications for 3rd Seoul Smart City Prize to Recognize Global Smart City Champions

  • Seoul calls for outstanding smart-city innovation projects from around the world until May 30th
  • A total of 21 prizes in three categories: Projects (Human-Centered & Technological Innovation Projects), Leadership, and Special Mention.
  • Awards ceremony to be held in conjunction with Smart Life Week (SLW) 2025 from September 30 to October 1, with international mayors and experts in attendance
  • Winners will gain opportunities for international promotion, including exhibitions and capacity-building programs

SEOUL, South Korea, March 28, 2025 /PRNewswire/ — The Seoul Metropolitan Government (SMG) has announced that applications for the 3rd Seoul Smart City Prize are open until May 30. The competition is open to city governments, institutions, corporations, and individuals worldwide to recognize outstanding smart city innovation policies.

3rd Seoul Smart City Prize Poster
3rd Seoul Smart City Prize Poster

  • Now in its third year, the Seoul Smart City Prize was established in 2023 by the Seoul Metropolitan Government in collaboration with the World Smart Sustainable Cities Organization (WeGO). Leveraging Seoul’s world-class digital government capabilities, the award aims to present a vision for the future of smart cities and promote the global adoption of smart-city ideas.

In the first competition in 2023, 240 entries were submitted from 93 cities across 47 countries, including Los Angeles (USA), Madrid (Spain), and São Paulo (Brazil). Last year, a total of 216 projects incorporating various innovative technologies such as Artificial Intelligence (AI), the Internet of Things (IoT), and Digital Twins were submitted by 123 cities from 58 countries, including London (UK), Helsinki (Finland), and Abu Dhabi (UAE).

  • Last year’s winners: the gold prize was awarded to two projects — ‘BIAG’, a health governance system from Baguio, Philippines, and ‘Improving the School System through Digital Transformation’ from Reykjavik, Iceland.

This year’s competition features a total of 21 awards across three main categories: Projects, Leadership, and Special Mention. Specifically, there are 16 awards in the Project category (8 for human-centered projects and 8 for technological innovation projects), 2 awards in the Leadership category, and 3 awards in the Special Mention category.

PRIZE CATEGORY

  • Human-Centered: Projects that are designed to prioritize digital inclusion in smart city development, thereby overcoming or mitigating the digital divide, and that aim to serve specific target groups among the citizen population, such as the elderly, youth, and the disabled.
  • Tech-Innovation: Projects that focus on integration of innovative policies and technologies in all sectors of society and domains ranging from mobility, safety, welfare, environment, energy, culture and governance.
  • Leadership: Individuals that have demonstrated leadership in developing or promoting the innovative use of technology and data to impact the lives of global citizens.
  • Special Mention: Projects selected together with a partner organization or corporation of WeGO on the basis of the project’s alignment with the values and missions of the partner organization or corporation.

Applications must be submitted by May 30, 2025, through the official Seoul Smart City Prize website (https://seoulsmartcityprize.com).

  • More information on the application process, evaluation criteria, and other relevant details is available in the Seoul Smart City Prize 2025 Guidelines on the website.

The awards ceremony will take place on September 30 at COEX, in conjunction with Smart Life Week (SLW) 2025. Approximately 300 participants, including mayors from around the world, experts, and scholars, are expected to attend the ceremony, making it a key platform for sharing excellent smart-city projects and facilitating policy exchange.

  • Winning cities will receive various benefits and support to enhance their global reputation and promote their best practices worldwide. The benefits include a dedicated exhibition booth at the SLW International City Pavilion and access to a smart city capacity-building program.

 

South Asian University (SAU), New Delhi Expands Academic Offerings and Opens Admissions for 2025-26

1,370 seats available for the 2025-26 session

NEW DELHI, March 28, 2025 /PRNewswire/ — South Asian University (SAU), established with the vision of ‘Knowledge Without Borders’, has opened admissions for the 2025-26 academic session. Prof. K K Aggarwal, President of SAU, reaffirmed the university’s commitment to world-class education and expanding academic opportunities across South Asia.

Beyond Borders, Beyond Limits: South Asian University (SAU), New Delhi Admissions Open Now
Beyond Borders, Beyond Limits: South Asian University (SAU), New Delhi Admissions Open Now

SAU, founded by the eight SAARC nations, has significantly expanded since moving to its 100-acre modern campus near Gurugram. After operating from a temporary location at Akbar Bhawan until 2022, SAU has embarked on a major growth phase. The introduction of a B.Tech in Computer Science and Engineering in 2024-25 marked the beginning of this expansion. Now, SAU is offering new programs, increasing its academic reach with approximately 1,370 seats available for the 2025-26 session.

Key highlights of SAU’s expansion include specialized B.Tech programs in Computer Science & Engineering with specializations in Artificial Intelligence & Machine Learning, Business Systems & Intelligence, Cybersecurity, and Data Science & AI. Additionally, a B.Tech in Mathematics and Computing has been introduced to equip students with advanced computational and analytical skills.

SAU has also launched Integrated Programs, such as the Integrated BS-MS in Interdisciplinary Sciences and the Integrated BBA-MBA program, ensuring a seamless transition from undergraduate to postgraduate studies. In alignment with global trends, the university now offers one-year Master’s programs for students with four-year undergraduate degrees, providing an accelerated path to postgraduate education. Expanded postgraduate offerings include an MBA, Executive MBA, MCA, and MS Climate Change and Sustainability, complementing existing programs like M.Tech, MSc (Computer Science), MSc Biotechnology, MA Sociology, MA International Relations, MA Economics, and LLM.

To strengthen research opportunities, SAU has introduced an Executive PhD program for working professionals. Admissions will be conducted through SAU’s entrance test and recognized national-level eligibility tests across SAARC nations, including CUET, JEE Mains, and CAT in India. Candidates from other SAARC nations can take a secure, proctored online entrance test or gain admission based on merit in their qualifying examinations.

SAU has also launched its Virtual Campus, offering online degree and certificate programs, such as BBA (Hons), BCA (Hons), Integrated BBA-MBA, BS and MS (Data Science & AI), MBA, and MCA, along with courses in vocal music, fashion design, and communication design.

Applications for the 2025-26 academic session are now open. For details, visit www.sau.int.

 

 

IASO Bio Announces Approval of New Drug Application for Equecabtagene Autoleucel by the Macau Pharmaceutical Administration Bureau

SHANGHAI, NANJING, China and SAN JOSE, Calif., March 28, 2025 /PRNewswire/ — IASO Biotherapeutics (“IASO Bio”), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Pharmaceutical Administration Bureau of the Macao Special Administrative Region (ISAF) has approved the New Drug Application (NDA) for Equecabtagene Autoleucel. This treatment is indicated for adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent.

This is the first NDA approval for Equecabtagene Autoleucel outside Mainland China. Equecabtagene Autoleucel (trade name: FUCASO) was approved by China’s National Medical Products Administration (NMPA) on June 30, 2023, for treating adult patients with relapsed or refractory multiple myeloma (R/RMM) who have received three or more lines of prior therapies, including at least one proteasome inhibitor and an immunomodulatory agent. On January 29 and February 14, 2025, the NDA for this product for the above indications was formally accepted by the Health Sciences Authority of Singapore and the Department of Health of Hong Kong, China, respectively.

The Macau NDA approval is based on data from the pivotal FUMANBA-1 trial (CTR20192510, NCT05066646), a China-based, multi-site, Phase I/II registrational study evaluating the efficacy and safety of equecabtagene autoleucel in patients with relapsed/refractory multiple myeloma (R/R MM). The results demonstrated that equecabtagene autoleucel achieves outstanding efficacy and a favorable safety profile.

Ms. Zhang Jinhua, Founder, Chairperson, and CEO of IASO Biotherapeutics, stated: 
“We are delighted that the New Drug Application (NDA) for equecabtagene autoleucel has been approved by the Macau Drug Administration—the product’s first NDA approval outside Mainland China, marking a significant milestone. Through our innovative ‘Manufactured in Nanjing, Supplied Globally’ model, we will ensure timely access to this CAR-T therapy for multiple myeloma patients in Macau.

In December last year, we successfully delivered our Nanjing-manufactured CAR-T therapy to patients in Hong Kong through the Named Patient Program (NPP). Subsequently, in January and February of this year, the NDAs for equecabtagene autoleucel were officially accepted by the Singapore Health Sciences Authority and the Hong Kong Department of Health, respectively. We are actively collaborating with regulatory authorities to advance the approval processes and look forward to delivering clinical benefits to patients in these regions at the earliest opportunity. Meanwhile, IASO Bio remains committed to expanding the global footprint of our CAR-T therapies, dedicated to providing more treatment options for multiple myeloma patients worldwide.”

About Multiple MyelomaMM)

Multiple myeloma (MM) is the second most common hematological malignancy globally. According to Globocan data, the global incidence of multiple myeloma in 2022 was 1.8 per 100,000 people, with a 5-year prevalence of 6.8 per 100,000. Despite progress in current anti-myeloma treatments, MM remains largely incurable with multiple relapses and tendency to develop refractoriness to several drug classes, presenting a major therapeutic challenge. Thus, there is an unmet need for new treatment options beyond these current anti-myeloma therapies for the treatment of relapsed or refractory MM, capable of achieving deep and durable responses.

About Equecabtagene Autoleucel

Equecabtagene Autoleucel is an innovative fully human anti-BCMA CAR-T cell therapy which uses lentivirus as a gene vector to transfect autologous T cells. The CAR contains a fully human scFv, CD8a hinge and transmembrane, and 4-1BB co-stimulatory and CD3ζactivation domains. Based on rigorous molecular structure screening and comprehensive in vitro and in vivo functional evaluations, FUCASO demonstrates rapid and potent efficacy, accompanied by exceptional long-term persistence in vivo, enabling patients to achieve higher and deeper responses, providing continuous protection and care for patients with multiple myeloma.

About IASO Bio

IASO Bio Founded in 2017, IASO Bio is a leading biopharmaceutical company specializing in the discovery, development, manufacturing, and commercialization of cutting-edge cell therapies and biologics. Initially focused on treatments for blood cancers, the company has strategically expanded into autoimmune diseases.

IASO Bio boasts a robust drug development platform, encompassing early discovery to clinical trials, regulatory approval, and commercialization. The company is advancing a diverse pipeline of over 10 innovative products. Notably, Equecabtagene Autoleucel (FUCASO), the world’s first fully human CAR-T therapy developed by IASO Bio was approved by Chinese National Medical Products Administration (NMPA) in June 2023 for the treatment of relapsed and/or refractory multiple myeloma (R/R MM) who received ≥3 lines of prior therapies containing at least one proteasome inhibitor and an immunomodulatory agent. relapsed/refractory multiple myeloma (R/RMM) in patients at the fourth line and beyond. This product is also in Phase III clinical trials for second and third-line multiple myeloma (MM) and has received Investigational New Drug (IND) approvals in both China and US for autoimmune diseases. Meanwhile, the dual-target (CD19/CD22) product, CT120, for lymphoma is entering Phase II clinical trials. Additionally, RD118, another product targeting GPRC5D for the treatment of R/R MM, has received IND approval in China.

In addition to CAR-T therapies, IASO Bio is advancing IASO-782, a fully human anti-CD19 monoclonal antibody. This product has secured IND approvals in China and USA for several autoimmune diseases, with plans to explore additional autoimmune indications.

IASO Bio has established multiple global collaborations and licensing agreements with leading cell therapy companies, such as Sana Therapeutics, Cabaletta Bio, and Umoja Biopharma, underscoring its superior technology platform and commitment to next-generation cell therapies.

With a strong management team, a robust pipeline, high-standard manufacturing and advanced clinical development capabilities, the company is well-positioned to drive innovation. It remains committed to accelerating the development of transformative therapies that address unmet medical needs for patients worldwide. For more information, please visit http://www.iasobio.com or www.linkedin.com/company/iasobiotherapeutics.

Rhenus Group expands Management Board to drive transformation and growth

  • Rhenus Group expands Management Board from four to seven members to reflect the Group’s significant transformation and growth ambition, elevating crucial roles to the highest level of decision-taking
  • Dr. Joana Bätz appointed member of the Rhenus Group Management Board with responsibility for the Group functions for Human Resources, Sustainability and Compliance
  • Jan Harnisch appointed member of the Rhenus Group Management Board for the Air & Ocean Division
  • Dr. Marcus Ewig appointed member of the Rhenus Group Management Board for the Automotive Division and Group Procurement, Health & Safety and Quality Management

SINGAPORE – Media OutReach Newswire – 28 March 2025 – Effective 1 April 2025, the Rhenus Group has appointed three experienced leaders from within the company to the Management Board. Dr. Joana Bätz will be representing the Group functions for Human Resources, Sustainability and Compliance, Jan Harnisch for Air & Ocean and Dr. Marcus Ewig for Automotive as well as the Group functions Procurement, Health & Safety and Quality Management. The expansion of the Management Board reflects the company’s transformation into a leading global logistics company, lifting crucial roles to the highest level of decision-taking and reinforcing the Group’s commitment to future growth.

Over the past three decades, Rhenus has evolved from a mid-sized German logistics company into the world’s largest family-owned logistics provider, offering resilient and integrated supply chain solutions tailored to the rapidly changing needs of diverse industries. To navigate the complexities of the global logistics market and drive sustainable transformation, Rhenus has recognized the need for enhanced leadership and strategic guidance at the highest level. The expansion of the Management Board is a key step in this direction.

“We are delighted to welcome three accomplished leaders in their respective areas of responsibility to the Management Board,” says Dr. Marco Schröter, Chairman of the Supervisory Board Rhenus Group. “These appointments demonstrate our commitment to leveraging our own talent and the deep expertise within Rhenus Group. Their combined experience will be invaluable as we navigate the evolving logistics landscape and pursue our ambitious growth path.”

“With the expansion of our Management Board we are reinforcing our people-centered approach and our commitment to future-proofing our company for generations to come. In addition, we are setting an important focus on strengthening all our divisions on a global level: in times of geopolitical volatility and rapidly changing market environments, we are ensuring that we can provide even more resilient, tailor-made logistics solutions for our customers and meet the specific needs of each industry even better,” adds Tobias Bartz, CEO Rhenus Group. “I have had the pleasure of working alongside these great colleagues for many years. Their operational expertise, strategic mindset, deep industry knowledge and their alignment with the unique Rhenus family values will be strong assets to the board. I’m delighted to welcome them and wish them every success in their new roles.”

New Board Member Appointments

With the appointment of Dr. Joana Bätz, Rhenus is giving top priority to its employees, the driving force behind the company’s success. Overseeing the Group functions for Human Resources, Compliance and Sustainability, she holds a key role in shaping the Group’s long-term strategy. Joana Bätz brings almost two decades of experience in the logistics sector, seven years of those spent with the Rhenus Group. She rapidly advanced into global leadership roles, before she was appointed Group CHRO in 2022. In this role, she implemented a professionalized Group-wide HR organization, significantly drove the company’s cultural change and brought people management to the next level by introducing HR technology solutions and launching a global employer brand. She received her doctorate from the Johann Wolfgang Goethe University, Frankfurt (Main), with a focus on Human Resources and Organizational Development.

Air & Ocean is now represented on the Board by its global CEO, Jan Harnisch, who has been with Rhenus since 2012. He has held leadership roles within the Air & Ocean Division at both global and regional levels, including Global COO since 2020 and Global CEO since 2022. Jan played a pivotal role in the division’s expansion into new international markets while driving operational excellence, digital transformation, and strategic growth. His focus is on scaling Rhenus Air & Ocean’s position as a global top player in freight forwarding by accelerating its international footprint, increasing agility, and advancing customer-centric logistics solutions that drive long-term value.

Dr. Marcus Ewig has been elevated to the Management Board from his role as CEO of Rhenus Automotive, a position he has held since 2017. His key achievements include leading the international expansion of Rhenus Automotive into China and the US, establishing a joint venture for battery lifecycle management, and continuously driving the divisions growth and success. Marcus Ewig can tap into his vast experience in the automotive sector, having held various leadership positions at Porsche. In addition to Automotive, he will also be responsible for the Group functions Procurement, Health & Safety and Quality Management. He earned his doctorate in business informatics at the University of Leipzig.

Moving forward, the Management Board of the Rhenus Group will have seven members: Tobias Bartz (CEO & Chairman), Gilles Delarue, Dr. Stephan Peters, Andreas Stöckli, Dr. Joana Bätz, Jan Harnisch, and Dr. Marcus Ewig, each contributing their unique expertise to drive the company’s continued success.
Hashtag: #Rhenus

The issuer is solely responsible for the content of this announcement.

About Rhenus Group

The Rhenus Group is one of the leading logistics specialists with global business operations and annual turnover amounting to EUR 7.5 billion. 40,000 employees work at 1,320 business sites in more than 70 countries and develop innovative solutions along the complete supply chain. Whether providing transport, warehousing, customs clearance or value-added services, the family-owned business pools its operations in various business units where the needs of customers are the major focus at all times.

Yanchang Petroleum International Announces 2024 Annual Results

Revenue and Profit of the Group Reached HK$29.18 Billion and HK$55.6 Million Respectively

***

Novus‘ operating performance remained resilience

Downstream oil and by-products trading business in China continued to growth

Results Highlights:

  • The Group’s revenue amounted to approximately (approx.) HK$29.18 billion, increased by 5% year-on-year (YoY);
  • Novus’ overall operating performance remained resilience in the face of sharp declines in oil and gas prices, exchange rates and production volume. It sold a total of 843,000 barrels of oil equivalent (BoE), generating sales revenue of CAD60,800,000. Benefiting from the impairment recovery of oil and gas assets of CAD25,260,000, Novus recorded a net profit of CAD11,600,000;
  • Cumulative oil sales volume of oil and by-product trading business in China amounted to 3,838,500 tonnes with an operating revenue of RMB27.034 billion and a net profit of RMB4.56 million.

HONG KONG, March 28, 2025 /PRNewswire/ — Yanchang Petroleum International Limited (“Yanchang Petroleum International” or the “Company“, together with its subsidiaries, the “Group“; Stock code: 346.HK) today announced its audited annual results for the year ended 31 December 2024 (“year under review”).

In 2024, the market maintained a “tight balance and weak” trend due to multiple factors such as the volatility in international oil prices, increasing geopolitical risk events and financial market turbulence. Facing external challenges, the Group adhered to its business philosophy, deepened the cost reduction and efficiency improvement of its oil and gas business, and strengthened its ability to hedge risks in the industrial chain. During the year under review, the Group actively engaged in technological innovation to improve recovery rates and operational efficiency in the upstream business, while the downstream business consolidated market resilience by promoting market expansion and deepening business cooperation. The Group’s revenue increased by 5% YoY to HK$29.18 billion in 2024, resulting in a profit of HK$55.6 million.

Upstream Oil and Gas Production Business in Canada

In 2024, Novus Energy Inc. (“Novus”) was committed to implementing the various work plans for 2024 and fully organised production and operations by focusing on key objectives of the year. During the year under review, Novus sold a total of 843,000 BoE, a decrease of 22.95% from the previous year. Sales revenue was CAD60,800,000, a decrease of 29.61% YoY. Natural gas sales prices continued to decline, representing a significant 41.02% YoY decrease. Sales prices of oil and gas mixtures decreased by 8.65%. Benefiting from the impairment recovery of oil and gas assets of CAD25,260,000, Novus recorded a net profit of CAD11,600,000.

During the year under review, Novus focused on the production targets for the year and made a concerted efforts to coordinate the production of new wells as well as control and reduction of production decline of old wells. In addition, Novus actively implemented effective optimisation measures for production and effectively controlled the decline in production for old wells. Novus produced a total of 837,000 BoE last year, successfully reaching the annual production target for the year.

In terms of reserves, Novus has taken a series of effective measures to maintain the sustainability of the reserves. Firstly, Novus has taken a number of initiatives to preserve the mining rights of lands and successfully preserved 68 square kilometers of lands. Secondly, through extensive drilling activities in recent years, the 2P reserves reached 18,520,000 BoE at the end of 2024, an increase of 2.3% YoY, which continuously consolidated the Group’s reserves. In addition, Novus successfully drilled an exploration well and put it into operation under the Madison Group, with cumulative production of 5,000 BoE in six months, laying the foundation for further exploration and development as well as reserves succession.

Downstream Oil and By-product Trading Business in China

In 2024, Henan Yanchang Petroleum Sales Co Ltd (“Henan Yanchang”) adhered to safe and compliant operations and firmly promoted market-oriented reforms. In the year under review, Henan Yanchang recorded cumulative oil sales volume of 3,838,500 tonnes, with an operating revenue of RMB27.034 billion and net profit of RMB4.56 million.

During the year under review, Henan Yanchang actively expanded its business development. In the retail terminal business, Henan Yanchang expanded the surrounding markets of gas stations and secured 36 new major customers. In terms of railway channel sales, benefited from its proactive expansion of sales channels and established long-term and stable cooperation with Sinopec, CNPC, as well as local state reserve and private enterprises, Henan Yanchang successfully cultivated partnerships with 10 new customers and realized a sales volume of 64,900 tonnes, with sales amounted to RMB464 million. In terms of external sourcing and sales, Henan Yanchang established stable cooperation with CNOOC Huadong Company, CNPC Hubei Company, Shell Chongqing Company and Shell Wuhan Company. Leveraging its core business, Henan Yanchang has expanded its sales in the Hubei, Hunan and Chongqing regions. During the year, the centralised procurement business reached 42,740 tonnes, establishing a strong market presence along the Yangtze River.

Mr. Feng Yinguo, Chairman of Yanchang Petroleum International, said, “In 2025, the international oil and gas market may face the two headwinds of weak demand recovery and high volatility in supply. The threat of a tariff war may slow down global economic growth, coupled with persistent geopolitical risks and energy policy uncertainties may further aggravate downward pressure on oil prices. The Group will continue to enhance the efficiency of its oil and gas business across the entire industry chain and strengthen its cost control and market responsiveness through digital tools, with a strategic focus on consolidating fundamentals and fostering new growth drivers. The Group is committed to excellence in its upstream and downstream businesses, creating sustainable value for our shareholders.”

– End – 

About Yanchang Petroleum International Limited (Stock code: 346.HK)

Yanchang Petroleum International is principally engaged in the following activities (i) exploration, exploitation, and operation of oil and gas; and (ii) fuel oil trading and distribution. In its upstream operations, Yanchang Petroleum International possesses operating oilfields in Saskatchewan and Alberta, Canada, through its wholly owned subsidiary Novus Energy Inc., a Canadian enterprise. Novus engages in the business of acquiring, exploring for, developing and producing crude oil and natural gas. In its downstream operations, Yanchang Petroleum International is principally engaged in wholesale, retail, storage and transportation of oil products through its 70% owned subsidiary, Henan Yanchang Petroleum Sales Co., Limited, and which has been granted valid licenses for distribution and sales of oil products in China.

For details, please refer to http://www.yanchanginternational.com

Mirae Asset Debuts Global X FTSE Greater China ETF (3470) with Cost-Competitive Access to Regional Markets

  • The new Global X FTSE Greater China ETF (3470) tracks the FTSE MPF Greater China Index which is designed for the MPF system.
  • This ETF enables investors track the overall market performance of the Greater China region at a competitive total expense ratio of 0.15%*.

HONG KONG, March 28, 2025 /PRNewswire/ — Mirae Asset Global Investments (Hong Kong) Limited, (the “Firm” or “Mirae Asset”) today announced the launch of its new Global X FTSE Greater China ETF (3470). The fund, which begins trading on the Hong Kong Stock Exchange (“HKEX”) today, offers investors exposure to large- and mid-cap companies in Mainland China, Hong Kong, and Taiwan that are listed on stock exchanges approved by the Mandatory Provident Fund Schemes Authority (“MPFA”).

The Global X FTSE Greater China ETF (3470) tracks the FTSE MPF Greater China Index, which serves as a benchmark for the Greater China region. The index is designed for the MPF system, incorporating investment restrictions and regulatory requirements applicable to the system. At a competitive total expense ratio of 0.15%*, the ETF provides investors with a cost-effective way to gain broad exposure to companies across various sectors in the region.

Recently the Greater China region has demonstrated market outperformance, compared to the broader Asia ex Japan market in recent years. Notably, the FTSE MPF Greater China Index delivered a 1-year return of 35.75%, compared to the FTSE MPF Asia Pacific ex Japan Index, which recorded 1-year return of 14.72%.[1] Amid global AI development, Taiwan’s semiconductor industry remains a key growth driver, while Hong Kong and A-shares markets have seen renewed interest from investors reassessing the China market. Through this ETF, it enables investors opportunities to capture the growth potentials in the region.

Mr. Wanyoun CHO, Chief Executive Officer of Mirae Asset Global Investments (Hong Kong) Limited, said: “We are delighted to introduce the Global X FTSE Greater China ETF. This launch shows Mirae Asset’s commitment to offering innovative investment solutions tailored to diverse investor needs, including those designed to cater the MPF system.”

With this new ETF, the Firm now offers a total of 38 ETFs listed in Hong Kong, spanning a diverse array of investment capabilities from core, thematic growth, income to commodities.

About Mirae Asset Global Investments Group

Mirae Asset Global Investments Group (the “group”) is an asset management organization with over US$256 billion in assets under management as of December 31, 2024[2]. The organization provides a diverse range of investment products including mutual funds, exchange traded funds (“ETFs”), and alternatives. Operating out of 25 offices worldwide, the group has a global team of more than 1,000 employees, including more than 280 investment professionals.

The group’s global ETF platform features a line-up of 629 ETFs that offer investors high quality and cost-efficient exposure to newly emerging investment themes and disruptive technologies in the global markets.[3] The group’s ETFs have combined assets under management of US$137 billion and are listed in Australia, Canada, Colombia, Hong Kong SAR, India, Japan, Korea, Vietnam, the EU, and the United States.[4]

About Global X ETFs

Global X ETFs was founded in 2008. For more than a decade, our mission has been empowering investors with unexplored and intelligent solutions. Our product line-up features 400 ETF strategies and over $90 billion in assets under management.[5] While we are distinguished for our Thematic Growth, Income, and International Access ETFs, we also offer Core, Commodity, and Alpha funds to suit a wide range of investment objectives. Global X is a member of Mirae Asset Financial Group, a global leader in financial services, has a presence in 19 global markets and the group’s managed assets exceed US$632 billion in assets under management worldwide.[6]

Mirae Asset Global Investments Hong Kong: https:/www.am.miraeasset.com.hk/ 
Global X ETFs Hong Kong:  www.globalxetfs.com.hk

Important Information

Investors should not base investment decisions on this material alone. Please refer to the Prospectus for details including product features and the risk factors. Investment involves risks. Past performance is not indicative of future performance. There is no guarantee of the repayment of the principal. Investors should note:

  • Global X FTSE Greater China ETF (the “Fund”)’s investment objective is to provide investment results that, before fees and expenses, closely correspond to the performance of the FTSE MPF Greater China Index (the “Index”).
  • The Fund is subject to concentration risk as a result of tracking the performance of a single geographical region or country (Greater China). The Fund may likely be more volatile than a broad-based fund, such as a global equity fund, as it is more susceptible to fluctuations in value of the Index resulting from adverse conditions in the region.
  • The Fund invests in certain emerging markets such as Mainland China and Taiwan. This may involve increased risks and special considerations not typically associated with investment in more developed markets, such as liquidity risks, currency risks/control, political and economic uncertainties, legal and taxation risks, settlement risks, custody risk and the likelihood of a high degree of volatility.
  • Listed companies on the ChiNext market and/or STAR Board are usually of emerging nature with smaller operating scale. In particular, listed companies on ChiNext market and/or STAR Board are subject to higher fluctuation in stock prices and liquidity risks, Over-valuation risk, Differences in regulation, Delisting risk, and Concentration risk.
  • The Fund may invest in mid-capitalisation companies, which may have lower liquidity and their prices are more volatile to adverse economic developments than those of larger capitalisation companies in general.
  • The borrower may fail to return the securities in a timely manner or at all. The Fund may as a result suffer from a loss or delay when recovering the securities lent out. This may restrict the Fund’s ability in meeting delivery or payment obligations from redemption requests. As part of the securities lending transactions, there is a risk of shortfall of collateral value due to inaccurate pricing of the securities lent or change of value of securities lent. This may cause significant losses to the Fund.
  • There are risks and uncertainties associated with the current Mainland China tax laws, regulations and practice in respect of capital gains realized via Stock Connect on the Fund’s investments in Mainland China (which may have retrospective effect). Any increased tax liabilities on the Fund may adversely affect the Fund’s value.
  • The trading price of the Shares on the SEHK is driven by market factors such as the demand and supply of the Shares. Therefore, the Shares may trade at a substantial premium or discount to the Fund’s Net Asset Value.
  • Payments of distributions out of capital or effectively out of capital amounts to a return or withdrawal of part of an investor’s original investment or from any capital gains attributable to that original investment. Any such distributions may result in an immediate reduction in the Net Asset Value per Share of the Fund and will reduce the capital available for future investment.

Disclaimer

This document is for Hong Kong investors only. This document is provided for information and illustrative purposes and is intended for your use only. It is not a solicitation, offer or recommendation to buy or sell any security or other financial instrument. The information contained in this document has been provided as a general market commentary only and does not constitute any form of regulated financial advice, legal, tax or other regulated services.

Certain of the statements contained in this document are statements of future expectations and other forward-looking statements. Views, opinions and estimates may change without notice and are based on a number of assumptions which may or may not eventuate or prove to be accurate. Actual results, performance or events may differ materially from those in such statements.

Investment involves risk. Past performance is not indicative of future performance. It cannot be guaranteed that the performance of the Funds will generate a return and there may be circumstances where no return is generated or the amount invested is lost. It may not be suitable for persons unfamiliar with the underlying securities or who are unwilling or unable to bear the risk of loss and ownership of such investment. Before making any investment decision, investors should read the Prospectus for details and the risk factors. Investors should ensure they fully understand the risks associated with the Funds and should also consider their own investment objective and risk tolerance level. Investors are advised to seek independent professional advice before making any investment.

Information and opinions presented in this document have been obtained or derived from sources which in the opinion of Mirae Asset Global Investments (Hong Kong) Limited (“MAGIHK”) are reliable, but we make no representation as to their accuracy or completeness. We accept no liability for a loss arising from the use of this document.

Products, services and information may not be available in your jurisdiction and may be offered by affiliates, subsidiaries and/or distributors of MAGIHK as stipulated by local laws and regulations. This document is not directed to any person in any jurisdiction where the availability of this document is prohibited. Persons in respect of whom such prohibitions apply or persons other than those specified above must not access this document. It is your responsibility to be aware of and to observe all applicable laws and regulations of any relevant jurisdiction. Please consult with your professional adviser for further information on the availability of products and services within your jurisdiction.

This document is issued by MAGIHK (Licensed by the Securities and Futures Commission for Types 1, 4 and 9 regulated activities under the Securities and Futures Ordinance). This document has not been reviewed by the Securities and Futures Commission or the applicable regulator in the jurisdiction in which this article is posted and no part of this publication may be reproduced in any form, or referred to in any other publication, without express written permission of MAGIHK.

Copyright © 2025 Mirae Asset Global Investments. All rights reserved.

*As the Fund is newly set up, this figure is an estimate only and represents the sum of the estimated ongoing charges over a 12-month period, expressed as a percentage of the estimated average Net Asset Value of the Listed Class of Shares over the same period. It may be different upon actual operation of the Fund and may vary from year to year. As the Fund adopts a single management fee structure, the estimated ongoing charges of the Fund will be equal to the amount of the single management fee, which is capped at 0.15% of the average Net Asset Value of the Listed Class of Shares of the Fund. Any ongoing expenses exceeding 0.15% of the average Net Asset Value of the Listed Class of Shares of the Fund will be borne by the Manager and will not be charged to the Fund.

[1] Source: Bloomberg, data as of 28 Feb 2025.

[2] Source: Mirae Asset Global Investments, December 31, 2024.

[3] Source: Mirae Asset Global Investments, December 31, 2024.

[4] Source: Mirae Asset Global Investments, December 31, 2024.

[5] Source: Mirae Asset Global Investments, December 31, 2024.

[6] Source: Mirae Asset Financial Group, September 30, 2024.

 

Vietnam Makes Its Biggest Drug Factory Bust, Seizes 1.4 Tons of Ketamine

Vietnam Makes Its Biggest Drug Factory Bust, Seizes 1.4 Tons of Ketamine
Vietnamese authorities investigate the drug factory (photo credit: VNExpress)

AFP – Police in Vietnam busted the country’s biggest synthetic drug factory, seizing 1.4 tons of ketamine in the coastal tourist city of Nha Trang, the government said.

Fangzhou Inc. Named Among Guangzhou’s Top AI Innovators for Intelligent Healthcare Platform

GUANGZHOU, China, March 28, 2025 /PRNewswire/ — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK),  a leader in Internet healthcare solutions, has been named to the 2024 Guangzhou Artificial Intelligence Innovation Development List as “Most Promising Enterprise,” while its H2H Smart Healthcare Ecosystem secured a spot on the “Application Scenario Innovation List” as a Top 10 AI+Healthcare Case. The awards, issued by the Guangzhou Municipal Science and Technology Bureau, highlight Fangzhou’s groundbreaking innovations in technology and its leadership in transforming the digital healthcare industry.

Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, commented, “Being recognized among Guangzhou’s top AI innovators reflects Fangzhou’s success in developing practical and scalable AI solutions for healthcare. This achievement reinforces our commitment to advancing an intelligent healthcare ecosystem that improves efficiency and accessibility.”

Strategic AI Collaboration with Tencent

Fangzhou has deepened its collaboration with Tencent Health and Tencent Cloud to accelerate AI-driven healthcare solutions, integrating the open-source DeepSeek-V3 and DeepSeek-R1 models into its platform. Following the local deployment of DeepSeek’s large language model in February, the partnership leverages Tencent’s cloud infrastructure to power Fangzhou’s upgraded “AI Agent 2.0” platform, targeting transformative applications in pharmaceutical logistics and healthcare services.

Flagship AI Modules for Enhanced Efficiency

The Company’s “AI + H2H Smart Healthcare Ecosystem” features four core AI modules: AI Physician Assistant, AI Customer Engagement Assistant, AI Procurement Orchestrator, and AI Content Assistant. These tools are designed to streamline operations — from diagnostics to supply chain management — while improving patient and customer experiences across the platform.

About Fangzhou Inc.

Fangzhou Inc. (06086.HK) is China’s leading online chronic disease management platform, serving 49.2 million registered users and 223,000 physicians (as of December 31, 2024). The Company specializes in delivering tailored medical care and precision medicine solutions. For more information, visit https://investors.jianke.com.

About the “Guangzhou Artificial Intelligence Innovation Development List”

Now in its third consecutive year, the “Guangzhou AI Innovation Development List” recognizes the city’s most impactful and promising artificial intelligence enterprises. By highlighting these industry leaders and their cutting-edge applications, the initiative strengthens collaboration across Guangzhou’s AI value chain and fosters a more connected ecosystem.

Media Contact
For further inquiries or interviews, please reach out to:
Xingwei Zhao Associate Director of Public Relations Email: pr@jianke.com 

Disclaimer: This press release contains forward-looking statements. Actual results may differ materially from those anticipated due to various factors. Readers are cautioned not to place undue reliance on these statements